Cara Therapeutics Inc (NASDAQ:CARA) Director Jeffrey L. Ives sold 2,500 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $25.83, for a total transaction of $64,575.00. Following the transaction, the director now directly owns 8,500 shares in the company, valued at $219,555. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of Cara Therapeutics stock opened at $16.76 on Friday. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $670.67 million, a P/E ratio of -8.13 and a beta of 2.30. The business has a fifty day simple moving average of $21.33 and a two-hundred day simple moving average of $21.58. Cara Therapeutics Inc has a 12 month low of $12.19 and a 12 month high of $27.55.
Cara Therapeutics (NASDAQ:CARA) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.15). The business had revenue of $5.79 million during the quarter, compared to analysts’ expectations of $5.56 million. Cara Therapeutics had a negative return on equity of 70.35% and a negative net margin of 470.70%. Analysts predict that Cara Therapeutics Inc will post -2.55 earnings per share for the current year.
Several equities research analysts have recently commented on the stock. BidaskClub raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Cantor Fitzgerald boosted their price target on shares of Cara Therapeutics from $29.00 to $33.00 in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $35.00 price target on shares of Cara Therapeutics in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Cara Therapeutics in a research note on Tuesday. Finally, Zacks Investment Research lowered shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Cara Therapeutics has a consensus rating of “Buy” and an average price target of $27.54.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Featured Article: Understanding Specialty Certificates of Deposit
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.